Tacrolimus
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Tacrolimus
- Tacrolimus: From Transplant Immunosuppression and Atopic Dermatitis to Seborrheic Dermatitis
Tacrolimus: From Transplant Immunosuppression and Atopic Dermatitis to Seborrheic Dermatitis
One-Sentence Summary
Tacrolimus is a calcineurin inhibitor. It is registered in South Africa as capsules and an infusion (systemic use) and as an ointment (topical use, Protopic). TxGNN predicts it may be effective for seborrheic dermatitis, and 2 completed clinical trials and 20 publications currently point in this direction. The published evidence includes a multicentre double-blind RCT of maintenance therapy on the face. This is a topical use only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA records supplied (indication text is blank). Registered forms suggest systemic use (capsule, infusion) and topical use (ointment). Confirm against the Professional Information (PI). |
| Predicted New Indication | Seborrheic dermatitis |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L2 (only one completed Phase 3 trial, so L1 is not met; see the note below the table) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 5 |
| Recommended Decision | Proceed with Guardrails |
Note on evidence level: the L1 rule requires at least 2 completed Phase 3 RCTs. Only NCT02004860 (Phase 3) meets that description for this indication. The other trial, NCT01591070, is Phase 4. The upstream pack labelled this L1, but by the stated criteria L2 is the safer grading.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the supplied record. From the literature, tacrolimus is a calcineurin inhibitor. It reduces T-cell activation and the release of pro-inflammatory cytokines (PMID 15461548, PMID 11145792).
Seborrheic dermatitis is a chronic, relapsing inflammatory skin disease of sebaceous areas, mainly the face and scalp. Its inflammation is thought to be driven by an immune response to Malassezia yeasts, so an anti-inflammatory calcineurin inhibitor is plausible (PMID 19222250, PMID 15663338). Topical corticosteroids are the usual anti-inflammatory option. Their long-term facial use is limited by adverse effects such as skin atrophy, whereas topical calcineurin inhibitors do not cause dermal atrophy (PMID 19222250, PMID 11807435). This makes tacrolimus ointment a candidate for maintenance treatment, where relapse prevention is the aim.
The link is therefore anti-inflammatory and topical. It does not rely on tacrolimus’s systemic immunosuppressive use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02004860 | Phase 3 | Completed | 120 | Protopic (tacrolimus) ointment as maintenance treatment of severe seborrheic dermatitis on the adult face. Aims to reduce relapse frequency, prolong remission and reduce topical steroid use. Results not provided in the pack. |
| NCT01591070 | Phase 4 | Completed | 104 | Proactive once- or twice-weekly 0.1% tacrolimus ointment to keep adult facial seborrheic dermatitis in remission and reduce exacerbations. Results not provided in the pack. |
No SANCTR or PACTR registrations were identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33010323 | 2021 | RCT (multicentre, double-blind) | J Am Acad Dermatol | Tacrolimus 0.1% vs ciclopiroxolamine 1% for maintenance in severe facial seborrheic dermatitis. The abstract notes no long-term maintenance therapy had previously been tested. |
| 24171300 | 2013 | RCT | Ann Parasitol | Sertaconazole 2% cream vs tacrolimus 0.03% cream in 60 patients with seborrheic dermatitis. |
| 37067129 | 2023 | Comparative study | Indian J Dermatol Venereol Leprol | Two days of oral itraconazole plus topical tacrolimus vs topical tacrolimus alone for maintenance in Vietnam. |
| 26512166 | 2015 | Clinical study | Ann Dermatol | Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment, applying the low-dose intermittent approach used in atopic dermatitis. |
| 12833030 | 2003 | Open pilot study | J Am Acad Dermatol | 18 patients on 0.1% tacrolimus for up to 28 days. 11 (61%) achieved 100% clearance. |
| 27804089 | 2017 | Systematic review | Am J Clin Dermatol | Topical treatment of facial seborrheic dermatitis. Covers antifungals, keratolytics and corticosteroids as the broad treatment categories. |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Topical calcineurin inhibitors described as a safe alternative to corticosteroids for seborrheic dermatitis. |
| 19213227 | 2009 | Review | J Drugs Dermatol | Current status and therapeutic horizons of facial seborrheic dermatitis. |
| 11770914 | 2001 | Review | Semin Cutan Med Surg | Topical tacrolimus and pimecrolimus as candidates for skin disorders beyond atopic dermatitis, including seborrheic dermatitis. |
| 15461548 | 2004 | Review | Expert Opin Pharmacother | Tacrolimus ointment in atopic dermatitis and other inflammatory skin diseases. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| A40/13.12/0219 | Protopic | Ointment | Not listed in the supplied record |
| A39/34/0647 | Prograf | Capsule | Not listed in the supplied record |
| 32/34/0561 | Prograf ampoule 1ml | Infusion | Not listed in the supplied record |
| 43/34/1051 | Graftac 0,5 | Capsule | Not listed in the supplied record |
| 51/32.16/0172 | Tacrum 0,5 Mg | Capsule | Not listed in the supplied record |
Only the ointment (Protopic) is relevant to the topical use proposed here. The capsule and infusion products are systemic formulations and are not appropriate for this indication.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 3 trial and a completed Phase 4 trial target this exact indication and drug. A published multicentre double-blind RCT supports maintenance use on the face, and the mechanism is plausible. However, the trial results are not in the pack, no guideline endorsement is documented, and the SAHPRA safety data are missing, so a full “Go” is not justified.
To proceed, the following is needed:
- SAHPRA PI warnings, contraindications and interaction data. This is a blocking gap for safety screening.
- Published results of NCT02004860 and NCT01591070, including relapse rates and safety.
- The registered indications of Protopic in South Africa, to confirm that seborrheic dermatitis is off-label.
- Guardrails: topical use only, on the face, within the label’s age and duration limits. Consider the boxed warning on long-term topical use.
- Guideline or specialist dermatology review of maintenance regimens.
- A mechanism of action record from DrugBank.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.